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Abstract. In comorbidity of chronic obstructive pul-
monary disease and urolithiasis with oxalic acid stones 
changes of erythropoiesis were found in 78,3 % of patients, 
in particular – 52,2 % corresponded to mild iron-deficiency 
anemia and in 26,1 % of patients – chronic disease anemia 
or their combination. These changes were accompanied by 
likely reduction of blood erythropoietin within 2,9-3,5 
times less (p<0,05). 
Key words: oxalates, anemia, iron deficiency, 
erythropoiesis. 
Introduction. In recent years disscussions 
about extrapulmonary manifestations of chronic obs-
tructive pulmonary disease (COPD), which influence 
the severity of COPD course, especially if the co-
morbid pathology is present have been held [2, 3, 4, 
5]. Extrapulmonary COPD manifestations form 
pathogenetic “vicious circle” of comorbid conditions 
resulting in bad therapeutic response on COPD ther-
apy [1, 2, 8, 9]. According to the department of exp-
erimental research of the clinic of the University of 
Bologna (Italy), "systemic chronic inflammatory 
process” ("inflammaging") may be a risk factor of 
comorbid renal pathology of inflammatory genesis in 
patients with COPD and clinical manifestation of 
genenic deficiency peroxomal liver enzyme of alani-
ne:glyoxylate aminotransferase (AGT / AGXT), as 
the formation of kidney stones (urolithiasis) of oxalic 
acid nature – oxalosis [7]. The course of oxalic uroli-
thiasis is often accompanied by anemic syndrome [5, 
9, 10]. The role of the pathogenic mechanisms of 
influence of erythropoiesis imbalance on develop-
ment of anemic syndrome in COPD and urolithiasis 
of oxalic acid origin is still unknown. There is a 
thought that compensatory production of eryth-
ropoietin due to hypoxia in COPD by slowing apopt-
osis of red bone marrow stem cells, inhibits hepsidin 
secretion. Hepcidin is a disulfide peptide produced in 
the liver, macrophages and adipocytes and is a key 
regulator of iron metabolism. As a result of these 
changes, even enough erythropoietin production does 
not prevent anemic syndrome in patients with COPD 
and urolithiasis of oxalic origin [6, 7, 11]. Thus, the 
problem of research of the mechanisms and variation 
of anemic syndrome in COPD and urolithiasis of 
oxalate genesis, its impact on patients’quality of life 
is not studied and so defines the value of this study. 
Objective. To determine pathogenetic links of 
erythropoietic disorders and clinical peculiarities of 
anemic syndrome in patients with comorbid COPD 
and urolithiasis of oxalate nature. 
Material and methods. The study involved 60 
patients who were divided into three groups. The 
first (Ist) group included 18 patients with urolithiasis 
of oxalic acid origin. The second (IInd) group inclu-
ded 19 patients with COPD (2B, 3C GOLD). The 
third (IIIrd) group included 23 patients with COPD 
(2B, 3C GOLD) with comorbid oxalate urolithiasis. 
The distribution of the patients by gender: males – 
38 (63,2 %), females – 22 (36,7 %). The average age 
of the patients was (55,9±3,3). 
The control group consisted of 20 practically 
healthy individuals: males - 13 (65,0 %), females – 7 
(35,0 %), who, at the time of involving into research, 
didn’t have any acute or chronic diseases and no 
allergic history . Age of examined individuals in the 
control group was (53,5±3,2). Absence of significant 
age and sex differences between the control and stu-
dy groups allowed to compare the data of these 
groups. 
The degree of bronchial obstruction and the risk 
of worsening of COPD course was estimated by the 
Ministry of Health of Ukraine protocol № 555 
(06.27.2013). Diagnosis of urolithiasis of oxalate 
origin was estimated according to the Ministry of 
Health of Ukraine protocol № 604 (06.12.2004). 
Inclusion criteria for patients of the Ist group 
were symptoms according to the Ministry of Health 
of Ukraine protocol № 604 (06.12.2004): shadows of 
concrements during ultrasound, impaired urody-
namics (renal pelvis dilatation), 24-h uri-
nary excretion of oxalate. Inclusion criteria for patie-
nts of the IInd group were the following: clinical 
symptoms according to the clinical protocol of COP-
D diagnosis of the Ministry of Health of Ukraine № 
555 (06.27.2013), stage (2B, 3C GOLD): expiratory 
dyspnea, chronic cough, chronic sputum discharge; 
recurrent COPD course with frequent exacerbations. 
COPD was diagnosed by GOLD 2013 according to 
the computer spirography with post-bronchodilatator 
FEV1. The severity of dyspnea was determined by a 
modified scale "Medical Research Council (mMRC) 
Dyspnea Scale". Pulmonary function test (PFT) was 
conducted on Spirometer"Microlab-3300" ("Sensor – 
Medics", Netherlands) with computer analysis of the 
results. To test the reversibility of bronchial obstr-
uction we used inhalation of β-agonist (salbutamol). 
The criteria for selection of patients to the IIIrd group 
was the presence of COPD (2B, 3C GOLD) with 
comorbid urolithiasis of oxalate genesis. 
Exclusion criteria were the following diseases: 
diabetes, coronary artery disease, acute coronary 
syndrome, myocardial infarction, valvular heart dis-
ease, heart failure (II-III stage ; III-IV FC with left 
ventricular ejection fraction below 45 %), acute cer-
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ebrovascular accident , rheumatic diseases 
(rheumatic fever, diffuse connective tissue diseases, 
etc.), oncology and infection; viral hepatitis B and C, 
cirrhosis of various etiologies, mental disorders, 
pregnancy or lactation, acute inflammation of any 
localization, other decompensated diseases or 
condition which may affect the results of the study.  
State of erythropoiesis and iron metabolism 
parameters were evaluated on blood count: the 
number of red blood cells and hemoglobin, the color 
index (CI), relative content of reticulocytes in blood, 
serum iron, transferrin (mcmol/l), ferritin (mkg/l) 
and erythropoietin (mIU / ml) which were 
determined in the laboratory "Synevo" (Chernivtsi). 
Transferrin level was determined on analyzer Cobas 
6000 (s501 module) of the test system Roche 
Diagnostics (Switzerland). Ferritin level was 
determined with immunochemical detection of 
(ECLIA) on the analyzer Cobas 6000 (e 601 module) 
and test system Roche Diagnostics (Switzerland). 
Erythropoietin level was determined by ELISA test 
system for the quantitative determination of 
erythropoietin in serum on Biomerica (USA) ana-
lyzer. 
Statistical analysis of the material was 
performed by the methods of variation statistics with 
the definition of averages (M), the average error (m). 
By taking a probable difference parameters at p 
<0,05 [9]. Probability changes in variations of 
samples with normal distribution were determined by 
paired Student's test, using IBM SPSS Statistics 20 
and Origin 8.0 programs. 
Results and discussion. Analysis of the results 
of the study showed (table 1) that patients of the Ist 
and IIIrd groups had significantly lower hemoglobin 
content in the blood than the control group: 23,6 % 
and 31,1 % less respectively (p<0,05). Number of 
red blood cells in the peripheral blood in all groups 
was significantly reduced: in the Ist and IInd groups 
34,0 % and 21,4 % less, with a maximum decrease in 
the IIIrd group 35,0 % less (p<0,05). The result of 
and IIIrd groups 21,3 % and 25,0 % (p<0,05) less 
respectively, compared with the data of the control 
group. The color index in all groups was in normal 
ranges. 
Analysis of iron metabolism shows significant 
reduction in the Ist and IIIrd groups when compared 
with a control one, 2,2 and 2,4 times less 
respectively (p<0,05). Similar changes of ferritin 
levels: decrease in groups I and III, respectively 2,5 
and 2,9 times less (p<0,05) and transferrin: 1,6 and 
1,8 times less (p<0,05) respectively, indicate a deep 
iron deficiency. These changes of iron transport 
forms mean the presence of iron deficiency, sidero-
penic syndrome in particular. The reason of these 
changes is that patients with oxalic urolithiasis have 
a constant loss of red blood cells due to chronic mi-
croscopic hematuria. 
At the same time, a significant reduction of 
erythropoietin in the blood was found in patients of 
the Ist and IIIrd groups, 1,6 and 2,7 times less(p<0,05) 
respectively, indicating the posthemorrhagic anemia 
with disorders of erythropoiesis regulation. 
Inhibition of erythropoietin production is present on 
the background of aseptic inflammation and 
incrustation of renal parenchyma with calcium 
oxalate crystals. 
In patients of the IIIrd group signs of 
erythropoiesis disorders were found alongside with 
anemic syndrome. In order to indicate the kind of 
anemic syndrome within this group of patients 
cluster analysis was performed: cluster 1: COPD 
patients with oxalic calculi urolithiasis without 
anemia; cluster 2: COPD patients with oxalic 
urolithiasis with anemia of chronic disease; cluster 3: 
COPD patients with oxalic acid urolithiasis with iron 
deficiency anemia (table 2). 
Cluster analysis of the group of patients with 
COPD and comorbid oxalate urolithiasis allowed to 
describe changes of erythropoiesis in more detailed 
manner. According to the blood count of these pa-
tients changes were the following: cluster 1were 
Table 1 
Indicators of erythropoiesis in group of patients with COPD and oxalic urolithiasis in comparison  
to groups of patients with isolated course of COPD and urolithiasis (M±m) 
Notes. *- changes are relevant in comparison with control group (р<0,05); ** - changes are relevant in comparison to group of 
patients with urolithiasis (р<0,05); *** - changes are relevant in comparison to group of patients with COPD (р<0,05)  






ІІІ ( COPD and  
urolithiasis )n=23 
Hb, g/l 125,0±9,7 95,4±4,7* 118,3±9,6 86,1±7,0*/*** 
Erythrocytes, 1012/l 5,0±0,3 3,3±0,2* 3,9±0,2* 3,25±0,18* 
Ht, % 45,1±2,7 35,4±1,8* 48,7±2,5** 33,32±1,9*/*** 
Color index 1,02±0,05 0,86±0,04 0,90±0,03 0,79±0,03 
Serum iron, mcmol/l 20,5±1,6 9,3±0,6* 17,7±1,2** 8,5±0,4*/*** 
Ferritin, mkg/l 81,0±5,1 32,1±4,2* 74,1±3,5 28,2±1,9*/*** 
Transferrin, mcmol/l 3,6±0,1 2,3±0,2* 3,5±0,2 2,05±0,10*/*** 
Erythropoietin, mIU / ml 29,2±1,8 18,3±0,9 * 25,7±1,3 10,9±0,57*/**/*** 
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classified as patients without anemic syndrome 
(21,7 % of the patients of the IIIrdgroup). The 2nd 
cluster: patients with chronic disease anemia (26,1 % 
of the patients of the IIIrdgroup), the 3rd cluster in-
volved patients with iron deficiency anemia 
(52,2 %). In patients of cluster 1the levels of 
hemoglobin, red blood cells and color index were 
within normal ranges. So in this subgroup anemic 
syndrome was not observed, although hemoglobin 
level was significantly lower than in the control 
group (p<0,05). Levels of serum iron, ferritin and 
erythropoietin indicate the normal state of 
erythropoiesis and iron stores in the body. 
Patients of cluster 2 had hemoglobin levels 1.6 
times less than in the control group (p<0,05). Red 
blood cells and color index levels were decreased 1,7 
times and 20,6 % less respectively compared to the 
same indicators in the control group. The content of 
serum iron corresponded with lower range of this 
indicator for adult individuals of this age group, but 
was significantly lower than in the control group 1,7 
times (p<0,05) less, indicating latent iron deficiency. 
These data were confirmed by normal levels of 
transferrin and erythropoietin with a tendency to 
decline (1,4 times less (p<0,05)) and (2,9 times less
(p<0.05)) respectively. According to the diagnostic 
criteria such data correspond with chronic disease 
anemia due to present COPD and urolithiasis. 
Formation of this condition in patients with COPD is 
caused by prolonged hypoxia and chronic 
inflammation that burst reactive oxygen species and 
pro-inflammatory factors into blood circulation. That 
causes inhibition of hematopoietic function of bone 
marrow. In this group of patients high excretion of 
calcium oxalate crystals in urine was found, so we 
can suggest that probable deposition of oxalate crys-
tals is also present in the bone marrow, which con-
tributes erythropoesis inhibition. This is confirmed 
by significantly reduced levels of erythropoietin. So, 
in patients of the 2nd cluster due to COPD and oxalic 
urolithiasis mild chronic disease anemia is present. 
In patients of cluster 3, decreased hemoglobin 
level (1,5 times less(p<0,05) compared with the level 
of hemoglobin in the control group) was found. The 
level of red blood cells was reduced 1.6 times less 
(p<0,05) compared with the level of red blood cells 
in patients of the control group. The level of color 
index was 23,5 % less (p<0,05) than color index 
level of the control group. These changes indicate 
the presence of hypochromic anemia. Erythropoietin 
level was reduced 3,5 times less(p<0,05) than in the 
control group. However, iron homeostasis in this 
cluster of patients indicates manifestation of sidero-
penic syndrome. In particular, reduced levels of 
serum iron (2,2 times less(p<0,05)), transferrin 1,8 
times less(p<0,05), significantly reduced blood 
levels of ferritin (7,5 times less(p<0,05)) than in the 
control group. According to the diagnostic criteria 
such data correspond with mild iron deficiency 
anemia. 
Comorbidity of COPD and urolithiasis with 
oxalic acid crystals accumulation results in release of 
oxidative stress cytokines and free radicals into not 
only bronchopulmonary, but the systemic circulation 
with activation of leukocytes and redistribution of 
iron. All these processes lead to anemia. It should be 
noticed that at the initial period, markers of chronic 
inflammation do not appear in the blood. In patients 
with urolithiasis of oxalic genesis, calcium oxalate 
crystals deposit in the bone marrow, suppressing 
erythropoiesis and in this way develop anemic 
syndrome or chronic disease anemia [7]. Anemic 
syndrome is due to insufficient secretion of 
erythropoietin in kidneys caused by urolithiasis 
which inhibits production of erythropoietin through 
depositing calcium oxalate crystals in the renal 
parenchyma. Chronic loss of red blood cells by he-
maturia depletes iron pool.  
Conclusion 
In 78,3 % of patients in the group with 
comorbid chronic obstructive pulmonary disease and 
oxalate urolithiasis changes of erythropoiesis were 
Table 2 
Indicators of erythropoiesis and iron metabolism in group of patients with COPD and  
oxalic urolithiasis after cluster analysis division 
Indicators, measure-
ments Control group 
Clusters of group of patients with COPD and urolithisis depending 
on changes in erythropoiesis 
Cluster 1 (n=5) Cluster 2 (n=6) Cluster 3 (n=12) 
Hb, g/l 125,0±9,7 120,1±6,2 80,7±4,2* 82,0±4,3 * 
Erythrocytes1012/l 5,0±0,3 3,8±0,2* 3,0±0,1* 3,1±0,1 * 
Color index 1,02±0,05 0,92±0,04 0,81±0,04* 0,78±0,03* 
Serum iron, mcmol/l 20,5±1,6 19,7±0,6 12,3±0,6* 9,3±0,4* 
Ferritin, mkg/l 81,0±5,1 76,1±1,5 57,2±1,9* 10,7±0,5* 
Transferrin, mcmol/l 3,6±0,1 3,6±0,2 3,9±0,2 2,0±0,1* 
Erythropoietin,  
mIU / ml 29,2±1,8 27,8±1,1 10,3±0,9* 8,3±0,4* 
Notes. *- changes are relevant in comparison with control group (р<0,05) 
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found. In particular: in 26,1 % of patients the chronic 
disease anemia was diagnosed, but mild iron defic-
deficiency anemia prevailed in 52,2 % of the patients 
in the group. General decrease in erythropoietin level 
within ranges of 2,9-3,.5 times less (p<0,05) than in 
control group was found. 
Prospect for further research is the devel-
development of methods of adequate correction of 
anemia in patients with COPD and comorbid oxalate 
urolithiasis, taking into consideration the mecha-
mechanisms of anemia pathogenesis. 
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ИЗМЕНЕНИЯ СИСТЕМЫ ЭРИТРОПОЭЗА ПРИ КОМОРБИДНОМ ТЕЧЕНИИ  
ХРОНИЧЕСКОГО ОБСТРУКТИВНОГО ЗАБОЛЕВАНИЯ ЛЕГКИХ  
И МОЧЕКАМЕННОЙ БОЛЕЗНИ 
О.С. Хухлина, К.В. Вилигорская 
Резюме. При коморбидном течении хроничского обструктивного заболевания легких и мочекаменной болез-
ни оксалатного генеза, у 78,3 % пациентов были установлены изменения в системе эритропоэза, которые у 52,2 % 
соответствовали железодефицитной анемии средней степени тяжести, а у 26,1 % пациентов - анемии хронического 
заболевания или их сочетанию, и сопровождались вероятным понижением уровня эритропоэтина в крови в преде-
лах 2,9-3,5 раза (p<0,05). 
Ключевые слова: оксалаты, ХОБЛ, МКБ, анемия, эритропоэз. 
ЗМІНИ СИСТЕМИ ЕРИТРОПОЕЗУ ЗА КОМОРБІДНОГО ПЕРЕБІГУ ХРОНІЧНОГО  
ОБСТРУКТИВНОГО ЗАХВОРЮВАННЯ ЛЕГЕНЬ ТА СЕЧОКАМ’ЯНОЇ ХВОРОБИ 
О.С. Хухліна, К.В. Вілігорська 
Резюме. За коморбідного перебігу хронічного обструктивного захворювання легень та сечокам’яної хвороби 
оксалатного генезу в 78,3 % пацієнтів встановлено зміни еритропоезу, які в 52,2 % відповідають залізодефіцитній 
анемії середнього ступеня тяжкості, а у 26,1 % пацієнтів – анемії хронічного захворювання, або їх поєднанню, і 
супроводжуються вірогідним зниженням вмісту в крові еритропоетину у межах 2,9-3,5 раза (p<0,05). 
Ключові слова: оксалати, ХОЗЛ, СКХ, анемія, еритропоез. 
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